A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamides immunotherapeutic effects
Jianpeng Yu, Xue Jiang, Haipei Yao, Zichun Xing, Fan Zhang, Chen Jin, Moyasar A. Alhamo, Hong Zhang, Bangchen Wang, Michelle L. Bowie, Olivia Meng, Daniel J. George, Robert Wild, Xia Gao, Yi Zhang, , Jiaoti Huang
This study shows that combining enzalutamide with DRP-104 enhances anti-tumor immunity by reducing Treg cells and improving CD8+ T cell activity in prostate cancer.
bioRxiv · Jul 1, 2026 · PreprintCancer Biology